Search

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Treatment, medicine and hematology research: What patients want and doctors need (to know)

Jan Geissler, a Patient Advocate remarked about the Congress: “Over and above scientific updates, much can be achieved in partnership between hematologists and patients.

Read more

How to apply for an EHA Bilateral Collaborative Grant

On this page, we explain all of the actions you'll need to take when submitting an EHA Bilateral Collaborative Grant application.

Read more

Last chance: special EAPM2017 registration offer for EHA members

EAMP2017 will take place in Belfast, Ireland, from 27-29 November 2017.  The European Alliance for Personalised Medicine (EAPM), launched in March 2012, brings together European healthcare experts and patient advocates involved with major chronic diseases.

Read more

PROFILE Bootcamp in Entrepreneurial Innovation in Orphan Diseases, October 23-25, 2017, Leuven, Belgium.

Breaking innovations in rare diseases are at the centre of this PROFILE Bootcamp, which brings together junior & senior researchers, clinicians, pharmaceutical industry and policymakers.

Read more

Cookie policy

Introduction
When you visit the EHA website and/or EHA’s resource platform(s) (this includes all websites and pages, with the exemption of www. t2evolve.

Read more